CGF166 / Novartis, Precigen - LARVOL DELTA

"Hello！Does cgf166 go well? Will it continue to the next stage?" (@irisZhe82020609)

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss (clinicaltrials.gov) - P1/2; N=22; Completed; Sponsor: Novartis Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion

"Does cgf166 go well? Will it continue to the next stage?" (@xinyue43042991)

"Not to mention the pandemic, how is CGF166?" (@xinyue43042991)

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss (clinicaltrials.gov) - P1/2; N=22; Active, not recruiting; Sponsor: Novartis Pharmaceuticals; Recruiting ➔ Active, not recruiting; N=45 ➔ 22

Enrollment change • Enrollment closed

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss (clinicaltrials.gov) - P1/2; N=45; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Feb 2021 ➔ Oct 2019; Trial primary completion date: Feb 2021 ➔ Oct 2019

Clinical • Trial completion date • Trial primary completion date

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss (clinicaltrials.gov) - P1/2; N=45; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Aug 2021 ➔ Feb 2021; Trial primary completion date: Aug 2021 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date